Precigen, Inc. (NASDAQ:PGEN) is one of the top strong buy stocks under $5 to buy now. H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on Precigen, Inc. (NASDAQ:PGEN) on August 19, keeping the associated price target the same at $8.50.
A technician holding a petri dish containing a DNA construction technology.
The analyst supported his positive rating with several factors, including the recent FDA approval of Papzimeos that surpassed expectations with its earlier-than-anticipated announcement.
He added that the approval encompasses a broad indication for recurrent respiratory papillomatosis, proving beneficial to around 27,000 adult American patients.
The label is favorable, including a broad indication and positive durability data, bolstering the drug’s market potential, according to the analyst.
Ramakanth also stated that Papzimeos has a promising financial outlook, with estimated sales of around $15 million in Q4 2025.
Precigen, Inc. is a biotechnology company involved in the research and development of synthetic biology technologies. The company’s operations are divided into the following segments: Biopharmaceuticals, Exemplar, and Trans Ova.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
This article is originally published at Insider Monkey.
